HHT nosebleed drug shows promise in long-term follow-up study

NCT ID NCT07018401

Completed Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study follows 62 adults with hereditary hemorrhagic telangiectasia (HHT) who previously took pomalidomide in a clinical trial. Researchers want to see if the drug safely reduces nosebleed severity and the need for iron or blood transfusions over time. Participants take pomalidomide by mouth daily, and their bleeding scores, blood counts, and side effects are tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pomalidomide (Pomalyst), a drug taken by mouth to reduce bleeding
What this could lead to: If it works, this could point toward a treatment that reduces severe nosebleeds and the need for iron infusions or blood transfusions in people with HHT.
What could go wrong: This is a small follow-up study with no placebo group, so results may be less reliable. Pomalidomide can cause side effects like low blood cell counts and blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary hemorrhagic telangiectasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

Contacts and locations

Locations

Cleveland Clinic

Cleveland, Ohio, 44195, United States
Johns Hopkins University

Baltimore, Maryland, 21218, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
University of California-San Diego

San Diego, California, 92093, United States
University of California-San Francisco

San Francisco, California, 94143, United States
University of Florida

Gainesville, Florida, 32610, United States
University of North Carolina, Chapel HIll

Chapel Hill, North Carolina, 27599, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Utah

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.